Sydney’s AXT offers Organ-on-Chip systems in Asia Pacific region
1 May 2019: Organ-on-Chip specialist CN Bio has signed a distribution agreement with Sydney-based AXT Pty. Ltd., Australia’s leading supplier of high technology scientific equipment. The agreement will see AXT distribute CN Bio’s innovative bioengineering products to medical researchers in academia and industry throughout Australia, New Zealand and the South Pacific region.
CN Bio is a leading lab-on-a-chip company, based in London. It’s flagship PhysioMimix device is being used by pharmaceutical, consumer goods companies and regulators globally.
The PhysioMimix Organ-on-Chip platform enables researchers to work with a wide range of cell types (iPSCs, primary cells, etc.) and commercial inserts to mimic human physiologyin vitro. This improves the efficiency of preclinical studies or industrial screening that require reliable human-relevant data.
CN Bio Commercial Director Paul Davies said: “PhysioMimix allows researchers to run single- and multi-organ human-tissue based studies, in parallel, on a compact lab-benchtop device.
“For teams who need human-relevant data as part of their research, preclinical testing, and to assess the safety or toxicity of new compounds, Organ-on-Chip studies are becoming absolutely invaluable. They provide comprehensive, 3D tissue-culture-based data and enable real-time monitoring and analysis.”
“AXT provide equipment to many of these teams already. A lot of groups in Australia and New Zealand are looking forward to adding the latest Organ-on-Chip techniques to their labs, and we’re delighted that they will have friendly faces to demonstrate and set up the CN Bio devices.”
Richard Trett, Managing Director of AXT said, “We are excited to bring CN Bio on board. Their addition to our existing portfolio continues our commitment to put the latest technologies in the hands of Australian researchers.
For Media Enquiries & Images: enquiries@cn-bio.com
AXT Enquiries: AXT has a diverse range of solutions for life science researchers. They cover areas such as cell biology, proteomics, genomics pharmacology, translational research etc. For more details, please visit www.axt.com.au
CN Bio Distribution & Partnership Enquiries: CN Bio welcomes AXT to its distribution partnership program. Suppliers of high end scientific and laboratory equipment interested in joining this program can contact enquiries@cn-bio.com
About PhysioMimix and CN Bio Innovations
CN Bio Innovations develops devices that boost the precision and speed of biological research. By predicting the effects chemical and biological substances will have on human organs, researchers can fast-track improvements in healthcare.
The PhysioMimix lab-benchtop device can be used to perform single-organ or multi-organ studies. Its open-well plates enable the formation of three-dimensional micro-tissues that mimic the structure and function of human organs. Linking two or more of these systems using microfluidics can reveal how multiple organs interact and respond to drugs or other chemicals. Cells and media can be sampled throughout experiments for analysis including biomarker assays, imaging to visualize cell morphology, cell migration and protein marker localization.
Researchers in biopharma, academic and regulatory laboratories globally are using PhysioMimix to study primary cells, stem cells, and organ mimetics including include liver, lung, gut, heart, kidney, skin, endometrium and brain. PhysioMimix is also being used by the US Food and Drug Administration (FDA) to conduct Organ-on-Chip assays.
Spun out from the University of Oxford, CN Bio is collaborating with and developing intellectual property from several leading UK and US universities including MIT, and is co-recipient of a grant from Defense Advanced Research Projects Agency (DARPA) for a 10-organ “Human-Body-on-a-Chip”.
For more information, visit www.physiomimix.com and www.cn-bio.com